GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Operating Income

CMRX (Chimerix) Operating Income : $-96.57 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chimerix Operating Income?

Chimerix's Operating Income for the three months ended in Dec. 2024 was $-24.55 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-96.57 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Chimerix's Operating Income for the three months ended in Dec. 2024 was $-24.55 Mil. Chimerix's Revenue for the three months ended in Dec. 2024 was $0.06 Mil. Therefore, Chimerix's Operating Margin % for the quarter that ended in Dec. 2024 was -43,073.68%.

Warning Sign:

Chimerix Inc operating margin has been in a 5-year decline. The average rate of decline per year is -142.4%.

Chimerix's 5-Year average Growth Rate for Operating Margin % was -142.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chimerix's annualized ROC % for the quarter that ended in Dec. 2024 was -496.48%. Chimerix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -7,173.70%.


Chimerix Operating Income Historical Data

The historical data trend for Chimerix's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Operating Income Chart

Chimerix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -44.52 -90.51 -60.39 -93.07 -96.57

Chimerix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.81 -24.39 -22.83 -24.79 -24.55

Chimerix Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-96.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (NAS:CMRX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chimerix's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-98.208 * ( 1 - 0% )/( (22.54 + 17.022)/ 2 )
=-98.208/19.781
=-496.48 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=146.008 - 16.906 - ( 131.643 - max(0, 23.871 - 135.951+131.643))
=17.022

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Chimerix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-98.208/( ( (1.37 + max(-17.572, 0)) + (1.368 + max(-20.318, 0)) )/ 2 )
=-98.208/( ( 1.37 + 1.368 )/ 2 )
=-98.208/1.369
=-7,173.70 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.155 + 0 + 4.517) - (17.47 + 0 + 4.774)
=-17.572

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.057 + 0 + 3.496) - (16.906 + 0 + 6.965)
=-20.318

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Chimerix's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-24.552/0.057
=-43,073.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Chimerix Operating Income Related Terms

Thank you for viewing the detailed overview of Chimerix's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Executives
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713